RIPK1 and amyotrophic lateral sclerosis: In the SOD1G93A mouse model of ALS, treatment with the RIPK1 inhibitor NEC-1 significantly reduced RRIM prevalence, indicating a reduction in pro-inflammatory microglia [192].